ArticleBMC surgery2025
Orthotopic liver transplant recipient with Enteric-coated Mycophenolate Sodium induced small bowel ulcers: two case reports.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEnteric-coated Mycophenolate Sodium(EC-MPS), one preparation of Mycophenolic acid(MPA), is an immunosuppressive drug commonly used after liver transplantation to prevent allograft rejection. EC-MPS induced small bowel ulcers are very rare and have not been reported in liver transplant recipients. Herein, we report two patients considered with small bowel ulcers induced by EC-MPS (a diagnosis of exclusion). CASE PRESENTATION: Case 1: A 56-year-old male complained of melena 40 days after orthotopic liver transplantation. Emergency esophagogastroduodenoscopy and colonoscopy did not find bleeding sites. His hemoglobin level was 47 g/L. Further small bowel endoscopy revealed an ulcer. EC-MPS was discontinued, and the small bowel capsule endoscopy showed the small bowel ulcer was completely healed 10 days later. The patient recovered well, and there was no melena during a follow-up period of 7 months. Case 2: Another 56-year-old male complained of melena 21 days after orthotopic liver transplantation. Emergency esophagogastroduodenoscopy and colonoscopy revealed mild esophageal varices and did not find active bleeding sources. His hemoglobin level was 68 g/L. Further small bowel endoscopy showed multiple large, irregular ulcers. Based on the clinical experience of managing case 1, EC-MPS was discontinued and substituted with mycophenolate mofetil (MMF). Then gastrointestinal hemorrhage was resolved, and enteral nutrition was gradually restored. Unfortunately, the patient ultimately died of a life-threatening infection.
conclusionAlthough usually regarded as a diagnosis of exclusion, liver transplantation recipients presented with small bowel ulcer need to be vigilant about the possibility of side effects of immunosuppressive agents, especially EC-MPS. Timely identification and adjustment of medication may improve the clinical outcome of patients. Heightened clinical awareness of this pharmacological association is strongly advocated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.